Navigation Links
AACR and Kure It announce 2 Kidney Cancer Research grant recipients
Date:12/21/2012

PHILADELPHIA The American Association for Cancer Research and Kure It are pleased to announce that William Y. Kim, M.D., and James W. Mier, M.D., will each receive a 2012 AACR-Kure It Grant for Kidney Cancer Research.

Kim, assistant professor in the departments of medicine and genetics at the University of North Carolina School of Medicine, in Chapel Hill, and Mier, associate professor at Harvard Medical School in the division of hematology and oncology at Beth Israel Deaconess Medical Center, in Boston, Mass., will each receive $250,000 during the two-year grant term. In addition, Kim and Mier will receive complementary registration to the AACR Annual Meeting 2013, to be held April 6-10 in Washington, D.C., and will be recognized at the Annual Grants Reception and Dinner on Tuesday, April 9.

These grants are designed to provide support for innovative translational kidney cancer research designed to improve the survival and quality of life of patients with kidney cancer and, in turn, lead to individualized therapeutic options for the treatment or development of promising new kidney cancer therapies.

Kim's project, "Defining the RCC [Renal Cell Carcinoma] Kinome for Target Discovery and Individualized Therapy," aims to personalize kinase therapy based on the patient's kidney tumor.

"Despite the fact that kidney cancer has very few activating mutations in kinases, they can be activated through alternate means and remain tenable therapeutic targets in renal cell carcinoma. We will use a novel, quantitative mass spectroscopy-based assay developed at University of North Carolina to assess the global activation state of the kinome and identify both novel as well as currently actionable targets," said Kim, a faculty member of UNC Lineberger Comprehensive Cancer Center.

Mier's research will explore the mechanism by which HDM2 antagonists and vascular endothelial growth factor-targeted drugs act together to block tumor angiogenesis and induce disease regression in renal cell carcinomas in his project, "HDM2/HDMX as a Therapeutic Target in Renal Cell Carcinoma." His work will support the ongoing translational kidney cancer research at Dana-Farber/Harvard Cancer Center.

"I am honored to have been selected for this grant and am grateful to Kure It and the AACR for making the funds available. Everyone in my lab feels encouraged by this award. We are planning to use the funds to carry out preclinical studies of novel agents that may prove useful in patients with RCC. The AACR-Kure It funds will allow us to carry out studies that we might otherwise not have been able to undertake," said Mier.

The expert scientific review committee, assembled by the AACR, received 44 high-caliber applications from independent investigators who proposed to develop and study new ideas and approaches that will have a direct application and relevance to patients with kidney cancer.

The AACR and Kure It are committed to collaboratively sustain the grant to award funding to the most promising kidney cancer research project.


'/>"/>
Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. The JAMA Network announces new names, new embargo schedules for specialty journals
2. Brain Spade Announces Site Launch is Now Set for January – New Year’s Resolutions Now Include Brain Health and Fitness
3. BrainTrain Announces Partnership with Elizabeth Shatner’s All Glory Project
4. HistoWiki.com's Clint Evans Announces Kindle Book Giveaway Which Shows the Missing Links from Michelle Obama's "Let's Move" Weight Loss Program
5. TherapySites (Websites for Therapists) Announces Partnership with Advanced Data Systems
6. Buckfire & Buckfire, P.C. Accident Attorneys Announce New Ugly Christmas Sweater Social Media Contest
7. Interlinked and InterlinkedTV Announce Heart Test Laboratories Exclusive Interview From NEAA
8. Renew Announces Online Treatment Finder, an Unbiased Rehab Center Guide
9. Bioforce AG Announces Doctors Comments Showing Efficacy of Echinaforce for Immune Support Now On You Tube
10. Andrew Hawley of Vintage Rock Posters Announces Finding a Vintage 1969 Jimi Hendrix 1969 Jahrhunderthalle Frankfurt Concert Poster
11. SpiritDetox.com Announces Addition of Herbal Clay Teas to Detox Product Lineup
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global ... is recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, ... move to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice ...
(Date:1/21/2017)... Pekin, IL (PRWEB) , ... January 21, 2017 , ... ... disorders. Even when individuals experience the freedom of recovery, they often feel shame for ... abuse and post-traumatic stress disorder (PTSD). In the workshop, “Rising Strong in Life After ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin and ... essential oils, announced the company had a successful visit to the 2017 ECRM Diet, ... gives companies that work in the nutritional, sports and health industries a chance to ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing in the ... is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of ... asked of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)...  Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage ... announced new additions to its senior leadership team: ... and Daniel Geffken as interim Chief Financial ... , Pharm.D. has been promoted to Chief Clinical Development ... Doug and Daniel to our management team, as both ...
Breaking Medicine Technology: